No annual revenue total was found in Curanex Pharmaceuticals Inc's SEC filings.
Curanex Pharmaceuticals Inc (CURX) files with the SEC under industry code 2834, Pharmaceutical Preparations. As of Jun 30, 2026 it held $2.9 million in cash and investments and $276,359 in total debt.
Revenue
—
Net income (TTM)
$-10.47M
Operating cash flow (TTM)
$-12.08M
Free cash flow
—
EPS (TTM)
$-0.38
Dividend per share
None
Shares outstanding
28.36M
Net cash
$2.66M
as of Jun 30, 2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CURX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Jericho, NY
- SEC filer status
- , Emerging growth company
- SEC CIK
- 2025942
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
|---|---|
| Operating income | -$4.2M |
| Net income | -$4.2M |
| Diluted EPS | -$0.17 |
| Operating cash flow | -$10.5M |
| Total assets | $11.6M |
| Total liabilities | $361,040 |
| Stockholders' equity | $11.2M |
| Cash and investments | $5.0M |
| Total debt | $346,699 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Oct 19, 2026 | Sep 14, 2026 |
| 8-K |
Current report
Other events
|
Sep 4, 2026 | Sep 3, 2026 |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change
|
Aug 17, 2026 | Aug 14, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
May 14, 2026 | May 14, 2026 |
| 10-Q | Quarterly report | May 14, 2026 | Mar 31, 2026 |
All 65 Curanex Pharmaceuticals Inc SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.